Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation Patients with Severe Kidney Disease or Undergoing Hemodialysis
Nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or undergoing hemodialysis were excluded from phase III randomized trials of nonvitamin K antagonist oral anticoagulants (NOACs). We sought to evaluate the effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with stage 4 or 5 chronic kidney disease or undergoing hemodialysis in routine practice.
Source: The American Journal of Medicine - Category: General Medicine Authors: Craig I. Coleman, Reinhold Kreutz, Nitesh Sood, Thomas J. Bunz, Daniel Eriksson, Anna-Katharina Meinecke, William L. Baker Tags: Clinical Research Study Source Type: research
More News: Atrial Fibrillation | Chronic Kidney Disease | Coumadin | Dialysis | General Medicine | Hemodialysis | Study | Urology & Nephrology | Warfarin